STUDY OBJECTIVES: To assess the knowledge of prescribers regarding intravenous to oral conversions of fluoroquinolones, the frequency and time until conversion, and to compare prescriber knowledge with the data collected concerning the reasons stated for continuation of intravenous fluoroquinolones. DESIGN: Prospective chart review and questionnaire. SETTING: Large teaching hospital in Paris, France. PATIENTS: Fifty-one males and females. INTERVENTION: Data were collected on in-patients receiving intravenous fluoroquinolone for at least three days and hospitalized in one of six in-patient units. Patients receiving intravenous fluoroquinolone for less than three days were excluded. A questionnaire to assess the awareness of a potential conversion was distributed to those practitioners who had patients reviewed during the data-collection phase. MAIN RESULTS: The questionnaire revealed the ten most common reasons for continuing intravenous administration for more than three days. However, the physicians agreed that most patients should be converted as soon as possible. Practice patterns differed, with only 17 of 51 patients actually converted to oral therapy. CONCLUSION: In theory, the clinicians were aware of when to perform the conversion. However, in practice, the frequency of conversion was lower than optimum. Changes in clinical practice are needed to decrease the costs of intravenous therapy, without jeopardizing quality of care.
STUDY OBJECTIVES: To assess the knowledge of prescribers regarding intravenous to oral conversions of fluoroquinolones, the frequency and time until conversion, and to compare prescriber knowledge with the data collected concerning the reasons stated for continuation of intravenous fluoroquinolones. DESIGN: Prospective chart review and questionnaire. SETTING: Large teaching hospital in Paris, France. PATIENTS: Fifty-one males and females. INTERVENTION: Data were collected on in-patients receiving intravenous fluoroquinolone for at least three days and hospitalized in one of six in-patient units. Patients receiving intravenous fluoroquinolone for less than three days were excluded. A questionnaire to assess the awareness of a potential conversion was distributed to those practitioners who had patients reviewed during the data-collection phase. MAIN RESULTS: The questionnaire revealed the ten most common reasons for continuing intravenous administration for more than three days. However, the physicians agreed that most patients should be converted as soon as possible. Practice patterns differed, with only 17 of 51 patients actually converted to oral therapy. CONCLUSION: In theory, the clinicians were aware of when to perform the conversion. However, in practice, the frequency of conversion was lower than optimum. Changes in clinical practice are needed to decrease the costs of intravenous therapy, without jeopardizing quality of care.
Authors: D Gangji; F Jacobs; J de Jonckheer; L Coppens; E Serruys; F Hanotte; S Motte; J P Thys Journal: Am J Med Date: 1989-11-30 Impact factor: 4.965
Authors: J A Ramirez; S Vargas; G W Ritter; M E Brier; A Wright; S Smith; D Newman; J Burke; M Mushtaq; A Huang Journal: Arch Intern Med Date: 1999-11-08
Authors: K G Przybylski; M J Rybak; P R Martin; C M Weingarten; F K Zaran; J G Stevenson; D P Levine Journal: Pharmacotherapy Date: 1997 Mar-Apr Impact factor: 4.705
Authors: M Amodio-Groton; A Madu; C N Madu; L L Briceland; M Seligman; P McMaster; M H Miller Journal: Ann Pharmacother Date: 1996-06 Impact factor: 3.154